论文部分内容阅读
Aim: To observe whether antithrombin agents affects the pharmacokinetic and pharmacodynamic properties of batifiban in combination therapy and optimize clinical administration dosage of batifiban.Methods: An open-label, parallel study was conducted.Thirty healthy subjects were randomly divided into three groups, which were sequentially treated with batifiban alone, or oral coadministration of clopidogrel, aspirin and UFH, or batifiban coadministered with these antithrombin agents.Blood samples were collected at pre-specified times.